Retension Pharmaceuticals and TRex Bio Filed for IPOs
The biotech firms have officially filed for U.S. public listings following a $350 million debut by Electra Therapeutics.
Updated on Sept. 18, 2026 in Biotech
Live Poll
Is now a good time for individual investors to participate in new biotech company IPOs?
Retension Pharmaceuticals and TRex Bio have filed paperwork for initial public offerings on the Nasdaq. These filings follow the recent market debut of Electra Therapeutics, which raised $350 million in its own upsized U.S. IPO.
Why it matters
The filings signal continuing capital market activity for clinical-stage biotechnology firms focused on chronic conditions. These companies aim to translate research in hypertension and autoimmune disease into public equity vehicles.
Electra Therapeutics successfully raised $350 million in an upsized IPO, setting a benchmark for recent biotech public market entries. TRex Bio currently maintains a clinical pipeline focused on autoimmune and inflammatory diseases.
The players
TRex Bio
A South San Francisco-based biotech firm developing treatments for autoimmune and inflammatory diseases.
Retension Pharmaceuticals
A Falls Church-based pharmaceutical company focused on hypertension and cardiovascular medicine.
Electra Therapeutics
A clinical-stage biotechnology developer that recently completed a $350 million U.S. public market debut.
Eli Lilly
A global pharmaceutical corporation that has announced plans to invest in the TRex Bio IPO.
The details
TRex Bio, headquartered in South San Francisco, specializes in therapeutic development for autoimmune and inflammatory conditions. Retension Pharmaceuticals, based in Falls Church, focuses on medications for hypertension and cardiovascular diseases. The firms will list on the Nasdaq exchange under the ticker symbols TRXB and RTSN, respectively.
Timeline
September 18, 2026: Retension Pharmaceuticals and TRex Bio submitted their IPO paperwork.
Mid-2027: TRex Bio expects to release clinical trial data for its TRB-061 program.
The Tech Race
The public listing of these companies reflects the ongoing effort to fund late-stage drug development via equity markets. The upcoming release of clinical trial data for TRB-061 serves as the key research milestone for TRex Bio as it transitions to a publicly traded entity.
These filings represent the first step in a public registration process that may eventually provide institutional and retail investors access to these companies. The clinical success of their drug candidates, such as TRB-061, will ultimately determine the potential availability of new cardiovascular and autoimmune therapies.
The takeaway
The move to public markets allows these firms to bolster balance sheets for their respective cardiovascular and autoimmune pipelines. Investors and researchers should monitor the mid-2027 TRB-061 clinical trial results as the primary indicator for TRex Bio's development progress.
What happens next
TRex Bio is scheduled to report data from its TRB-061 clinical trial in mid-2027.
Further reading
For more on the latest market movements in this sector, visit Biotech.
Live Poll
Is now a good time for individual investors to participate in new biotech company IPOs?
